221 related articles for article (PubMed ID: 23619367)
1. Recent advances in niacin and lipid metabolism.
Kamanna VS; Ganji SH; Kashyap ML
Curr Opin Lipidol; 2013 Jun; 24(3):239-45. PubMed ID: 23619367
[TBL] [Abstract][Full Text] [Related]
2. The high-fat high-fructose hamster as an animal model for niacin's biological activities in humans.
Connolly BA; O'Connell DP; Lamon-Fava S; LeBlanc DF; Kuang YL; Schaefer EJ; Coppage AL; Benedict CR; Kiritsy CP; Bachovchin WW
Metabolism; 2013 Dec; 62(12):1840-9. PubMed ID: 24035454
[TBL] [Abstract][Full Text] [Related]
3. Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents?
Kamanna VS; Kashyap ML
Am J Cardiol; 2007 Dec; 100(11 A):S53-61. PubMed ID: 18047854
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of action of niacin.
Kamanna VS; Kashyap ML
Am J Cardiol; 2008 Apr; 101(8A):20B-26B. PubMed ID: 18375237
[TBL] [Abstract][Full Text] [Related]
5. Niacin and cholesterol: role in cardiovascular disease (review).
Ganji SH; Kamanna VS; Kashyap ML
J Nutr Biochem; 2003 Jun; 14(6):298-305. PubMed ID: 12873710
[TBL] [Abstract][Full Text] [Related]
6. Differential tissue and ligand-dependent signaling of GPR109A receptor: implications for anti-atherosclerotic therapeutic potential.
Gaidarov I; Chen X; Anthony T; Maciejewski-Lenoir D; Liaw C; Unett DJ
Cell Signal; 2013 Oct; 25(10):2003-16. PubMed ID: 23770183
[TBL] [Abstract][Full Text] [Related]
7. Nicotinic acid: recent developments.
Kamanna VS; Vo A; Kashyap ML
Curr Opin Cardiol; 2008 Jul; 23(4):393-8. PubMed ID: 18520725
[TBL] [Abstract][Full Text] [Related]
8. Niacin: an old drug rejuvenated.
Kamanna VS; Ganji SH; Kashyap ML
Curr Atheroscler Rep; 2009 Jan; 11(1):45-51. PubMed ID: 19080727
[TBL] [Abstract][Full Text] [Related]
9. Modulation of HDL metabolism by the niacin receptor GPR109A in mouse hepatocytes.
Li X; Millar JS; Brownell N; Briand F; Rader DJ
Biochem Pharmacol; 2010 Nov; 80(9):1450-7. PubMed ID: 20655299
[TBL] [Abstract][Full Text] [Related]
10. Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells.
Lukasova M; Malaval C; Gille A; Kero J; Offermanns S
J Clin Invest; 2011 Mar; 121(3):1163-73. PubMed ID: 21317532
[TBL] [Abstract][Full Text] [Related]
11. Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression.
Lauring B; Taggart AK; Tata JR; Dunbar R; Caro L; Cheng K; Chin J; Colletti SL; Cote J; Khalilieh S; Liu J; Luo WL; Maclean AA; Peterson LB; Polis AB; Sirah W; Wu TJ; Liu X; Jin L; Wu K; Boatman PD; Semple G; Behan DP; Connolly DT; Lai E; Wagner JA; Wright SD; Cuffie C; Mitchel YB; Rader DJ; Paolini JF; Waters MG; Plump A
Sci Transl Med; 2012 Aug; 4(148):148ra115. PubMed ID: 22914621
[TBL] [Abstract][Full Text] [Related]
12. Pleiotropic effects of niacin: Current possibilities for its clinical use.
Zeman M; Vecka M; Perlík F; Staňková B; Hromádka R; Tvrzická E; Širc J; Hrib J; Žák A
Acta Pharm; 2016 Dec; 66(4):449-469. PubMed ID: 27749252
[TBL] [Abstract][Full Text] [Related]
13. Beyond LDL-cholesterol: HDL-cholesterol as a target for atherosclerosis prevention.
Parhofer KG
Exp Clin Endocrinol Diabetes; 2005 Sep; 113(8):414-7. PubMed ID: 16151973
[TBL] [Abstract][Full Text] [Related]
14. Effects of phenotypic and genotypic factors on the lipid responses to niacin in Chinese patients with dyslipidemia.
Hu M; Yang YL; Ng CF; Lee CP; Lee VWY; Hanada H; Masuda D; Yamashita S; Tomlinson B
Medicine (Baltimore); 2015 May; 94(20):e881. PubMed ID: 25997070
[TBL] [Abstract][Full Text] [Related]
15. Novel therapies to increase apolipoprotein AI and HDL for the treatment of atherosclerosis.
Wong NC
Curr Opin Investig Drugs; 2007 Sep; 8(9):718-28. PubMed ID: 17729183
[TBL] [Abstract][Full Text] [Related]
16. Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid.
Pike NB
J Clin Invest; 2005 Dec; 115(12):3400-3. PubMed ID: 16322787
[TBL] [Abstract][Full Text] [Related]
17. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing.
Benyó Z; Gille A; Kero J; Csiky M; Suchánková MC; Nüsing RM; Moers A; Pfeffer K; Offermanns S
J Clin Invest; 2005 Dec; 115(12):3634-40. PubMed ID: 16322797
[TBL] [Abstract][Full Text] [Related]
18. Niacin therapy in atherosclerosis.
Meyers CD; Kamanna VS; Kashyap ML
Curr Opin Lipidol; 2004 Dec; 15(6):659-65. PubMed ID: 15529025
[TBL] [Abstract][Full Text] [Related]
19. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice.
van der Hoorn JW; de Haan W; Berbée JF; Havekes LM; Jukema JW; Rensen PC; Princen HM
Arterioscler Thromb Vasc Biol; 2008 Nov; 28(11):2016-22. PubMed ID: 18669886
[TBL] [Abstract][Full Text] [Related]
20. Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia.
Vosper H
Br J Pharmacol; 2009 Sep; 158(2):429-41. PubMed ID: 19627285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
